Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
Several medicines that have already secured regulatory approval will not be included in Japan’s new drug price listings set to take effect March 18, Jiho has learned. These include GSK’s Exdensur (depemokimab) and Eli Lilly’s Inluriyo (imlunestrant), both approved in…
To read the full story
Related Article
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Recordati Snags Japan Rights to BMS’ Myelofibrosis Med Inrebic
December 19, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
REGULATORY
- Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
April 21, 2026
- Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
April 21, 2026
- Japan Launches Panel to Promote Radiopharmaceuticals
April 21, 2026
- LDP Project Team to Seek Patent-Period Price Maintenance in Growth Strategy Proposal
April 21, 2026
- Zepbound’s OSA Indication Up for Panel Review on April 24
April 20, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…